Plus Therapeutics Inc. [NASDAQ: PSTV] slipped around -0.65 points on Tuesday, while shares priced at $3.10 at the close of the session, down -17.33%. The company report on February 23, 2021 that Plus Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Business Highlights.
– Positive interim data through cohort five for the ReSPECT™ Phase 1 clinical trial in recurrent glioblastoma, announced November 2020 –.
– Completed sixth dosing cohort in ReSPECT™ December 2020 –.
Plus Therapeutics Inc. stock is now 53.47% up from its year-to-date (YTD) trading value. PSTV Stock saw the intraday high of $3.4253 and lowest of $2.80 per share. The company’s 52-week high price is 5.42, which means current price is +52.78% above from all time high which was touched on 02/10/21.
Compared to the average trading volume of 852.05K shares, PSTV reached a trading volume of 1210516 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Plus Therapeutics Inc. [PSTV]?
Ladenburg Thalmann have made an estimate for Plus Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 25, 2021. While these analysts kept the previous recommendation, Maxim Group raised their target price to Buy. The new note on the price target was released on October 16, 2020, representing the official price target for Plus Therapeutics Inc. stock.
The Average True Range (ATR) for Plus Therapeutics Inc. is set at 0.45, with the Price to Sales ratio for PSTV stock in the period of the last 12 months amounting to 9.28. The Price to Book ratio for the last quarter was 5.17, with the Price to Cash per share for the same quarter was set at 1.69.
How has PSTV stock performed recently?
Plus Therapeutics Inc. [PSTV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -11.43. With this latest performance, PSTV shares gained by 27.57% in over the last four-week period, additionally plugging by 17.87% over the last 6 months – not to mention a rise of 45.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PSTV stock in for the last two-week period is set at 52.22, with the RSI for the last a single of trading hit 47.95, and the three-weeks RSI is set at 54.11 for Plus Therapeutics Inc. [PSTV]. The present Moving Average for the last 50 days of trading for this stock 2.54, while it was recorded at 3.43 for the last single week of trading, and 2.39 for the last 200 days.
Plus Therapeutics Inc. [PSTV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Plus Therapeutics Inc. [PSTV] shares currently have an operating margin of -52.26. Plus Therapeutics Inc.’s Net Margin is presently recorded at -46.91.
Return on Total Capital for PSTV is now -22.46, given the latest momentum, and Return on Invested Capital for the company is -93.39. Return on Equity for this stock declined to -102.83, with Return on Assets sitting at -13.91. When it comes to the capital structure of this company, Plus Therapeutics Inc. [PSTV] has a Total Debt to Total Equity ratio set at 1,032.16. Additionally, PSTV Total Debt to Total Capital is recorded at 91.17, with Total Debt to Total Assets ending up at 51.54. Long-Term Debt to Equity for the company is recorded at 55.69, with the Long-Term Debt to Total Capital now at 4.92.
Reflecting on the efficiency of the workforce at the company, Plus Therapeutics Inc. [PSTV] managed to generate an average of -$273,583 per employee. Receivables Turnover for the company is 8.28 with a Total Asset Turnover recorded at a value of 0.30.Plus Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.00 and a Current Ratio set at 1.00.
Earnings analysis for Plus Therapeutics Inc. [PSTV]
With the latest financial reports released by the company, Plus Therapeutics Inc. posted -0.28/share EPS, while the average EPS was predicted by analysts to be reported at -0.75/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 62.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PSTV.
Insider trade positions for Plus Therapeutics Inc. [PSTV]
There are presently around $1 million, or 8.90% of PSTV stock, in the hands of institutional investors. The top three institutional holders of PSTV stocks are: BLACKROCK INC. with ownership of 121,038, which is approximately 0% of the company’s market cap and around 0.40% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 106,100 shares of the stock with an approximate value of $0.33 million in PSTV stocks shares; and TWO SIGMA INVESTMENTS, LP, currently with $0.18 million in PSTV stock with ownership of nearly 243.711% of the company’s market capitalization.
Positions in Plus Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 8 institutional holders increased their position in Plus Therapeutics Inc. [NASDAQ:PSTV] by around 180,346 shares. Additionally, 8 investors decreased positions by around 115,980 shares, while 5 investors held positions by with 88,239 shares. The mentioned changes placed institutional holdings at 384,565 shares, according to the latest SEC report filing. PSTV stock had 3 new institutional investments in for a total of 60,688 shares, while 4 institutional investors sold positions of 104,729 shares during the same period.